Infliximab and rate of mechanical
ventilation in COVID-19
patients:
The rate of mechanical ventilation was not statistically significant
between the two groups according to this meta-analysis.
Monoclonal antibodies could slightly decrease the rate of mechanical
ventilation in hospitalized patients with COVID-19 (relative risk 0.74;
95% confidence interval [CI], 0.60-0.9; I2 = 20%) [24].
Infliximab may potentially induce pulmonary complications like
non-infectious interstitial lung disease and thereby should be
cautiously prescribed in patients with SARS-CoV-2 [26].